Oncology

Latest News

Patient with cancer undergoing chemotherapy | Image credit: RFBSIP – stock.adobe.com

Many Patients With Advanced Cancer Report Care Misaligned With Their Goals

By Hayden E. Klein

August 25th 2025

The study found no difference in physician communication scores between patients with advanced cancer and other illnesses, suggesting that discordance may stem from other dynamics.

Innovation vs Affordability: Cancer Care’s Cost Crisis and Access Gap

Innovation vs Affordability: Cancer Care’s Cost Crisis and Access Gap

By Cameron Santoro

August 21st 2025

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

August 25th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 25th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

March 24th 2015

Race a Risk Factor for Cancer Mortality, Study Shows

Published in the Journal of the National Cancer Institute, the study found that most Asian subgroups were less likely to die from cancer than non-Hispanic white patients.

March 23rd 2015

Forcing Leukemia Cells to Behave

During laboratory experiments, while growing these leukemic cells, the authors observed that some of the cancer cells in culture were changing shape and size into what looked like macrophages. Subsequent experiments confirmed that by manipulating some of the transcription factors, these human cancer cells could be transformed into macrophages, which can engulf and digest cancer cells and pathogens.

March 23rd 2015

Alternative Medicine Can Boost Patient Survival

A retrospective review of evidence from studies that assessed the use of mind—body interventions, nutrition, physical activity, and combined complementary and alternative medicine approaches in cancer patients found not just improved disease support in cancer patients, but often times, improved survival as well.

March 23rd 2015

State Oncology Societies Join ASCO's Call on Congress to Replace SGR Formula

In a show of solidarity, state oncology societies from across the United States today joined the American Society of Clinical Oncology in its call on Congress to repeal Medicare's Sustainable Growth Rate formula before the current payment patch expires at the end of the month.

March 20th 2015

Novartis/Sandoz Clear to Market Their Biosimilar Zarxio

Zarxio was approved earlier this month, the first biosimilar to be approved in the United States.

March 20th 2015

Expanding the Reach of mHealth Among Low-Income Populations

The study, conducted by Elissa Ozanne, PhD, at Dartmouth found that 11 of the 15 women, aged 45-79 years, interviewed before and after using the mHealth tool preferred it to a paper tool and found it easy to use.

March 19th 2015

Stakeholders Provide Insight on the Oncology Care Model

Payers, oncologists, and oncology policy experts provide their feedback on the Oncology Care Model developed by the Centers for Medicare and Medicaid Innovation, which aims to link payment to the quality of care, improve access to care, and enhance information sharing.

March 19th 2015

COA Supports Bipartisan Bill to Prevent Medicare Sequestration Cuts in Oncology

"It's so ironic that CMMI, the innovation arm of CMS, is trying to sell us on implementing a new payment model for oncology while community oncology practices are struggling financially to keep their doors open because of CMS payment cuts," said Ted Okon, executive director, Community Oncology Alliance.

March 19th 2015

UCLA Researchers Develop Program to Tackle Post-Chemo Cognitive Lapses

Training sessions with a psychologist, in women treated for breast cancer, helped women with their memory and to maintain their ability to pay attention to things-the so called "executive function and planning" activities.

March 18th 2015

Leading Healthcare Economists and Policy Experts Shed Light on Cancer Drug Costs

The paper, published in the latest issue of the Journal of Economic Perspectives, found that while drug price was related to quality improvement over existing therapies, the price increase surpassed quality.

March 18th 2015

Radioactive Nanoparticles to Specifically Target Neuroblastomas

Developed at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, the technology uses tiny radioactive liposomes, inserted directly into a tumor with a thin catheter. The first-in-human trial was just initiated.

March 18th 2015

Discovery Points to Role of Macrophages in Melanoma Drug Resistance

Researchers have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments, they say. The results were published in the journal Clinical Cancer Research.

Session on Cardio-Oncology Reflects Growing Number of Survivors

March 17th 2015

Session on Cardio-Oncology Reflects Growing Number of Survivors

The Cardio-Oncology Intensive during the Annual Scientific Session of the American College of Cardiology reflects the increased need for improved diagnostic tools and cardioprotective strategies as cancer patients live longer. Besides a second malignancy, heart disease accounts for most morbidity and death in cancer survivors.

March 17th 2015

QALY: A Barrier for Patient Access to New Anticancer Agents?

The report by IMS Institute for Healthcare Informatics says countries that use a QALY formula to assess cost-effectiveness have less access to new cancer drugs compared with countries that use an alternative system.

March 17th 2015

Encouraging Results from Imbruvica in CLL and Small Lymphocytic Lymphoma

Improved survival without disease progression prompted independent reviewers to unblind the study comparing Imbruvica against a placebo, in combination with bendamustine and rituximab.

March 16th 2015

Circulating Plasma DNA Could be a Viable Alternative to Tumor Biopsy

The diagnostic test, which has been validated in breast, lung, colorectal, skin, and prostate cancers, requires sample submission to Guardant's CLIA-certified laboratory. The test, currently priced at $4900, maybe covered by payers where genomic profiling is needed and conventional biopsy is not an option.

March 16th 2015

Oncologists Raise a Voice Against Cancer Drug Costs

Hagop Kantarjian, MD, from MD Anderson is at it again. A special publication online, written in collaboration with S. Vincent Kumar, MD, from the Mayo Clinic, highlights the dismal state of the economics behind high oncology drug costs and recommends solutions.

Augmenting the Immune System to Achieve Great Outcomes in Cancer Care

March 15th 2015

Augmenting the Immune System to Achieve Great Outcomes in Cancer Care

Laura Joszt, MA

During the session "Principles of Immunotherapy" at the National Comprehensive Cancer Network 20th Annual Conference, Anthony J. Olszanski, RPh, MD, from the Fox Chase Cancer Center, described the complex interplay between the immune system and cancer, and some of the current immunotherapies being used today.

Dr Clifford Goodman Outlines the Pros and Cons of NCCN Guidelines

March 14th 2015

Dr Clifford Goodman Outlines the Pros and Cons of NCCN Guidelines

Over the years, the National Comprehensive Cancer Network Guidelines have become the market leader for clinical guidelines to consult, but with that success comes responsibility and scrutiny, according to Clifford Goodman, PhD.

Mary Lou Smith on Bringing Better Cancer Care to the Community

March 14th 2015

Mary Lou Smith on Bringing Better Cancer Care to the Community

The National Comprehensive Cancer Network Guidelines bring the practices of cancer care thought leaders out to the community, said Mary Lou Smith, JD, MBA, co-founder of the Research Advocacy Network.

NCCN Unveils New Smoking Cessation Guidelines

March 14th 2015

NCCN Unveils New Smoking Cessation Guidelines

Laura Joszt, MA

The most recent Surgeon General Report on Smoking and Health initiated the decision to create smoking cessation guidelines for cancer patients, Peter G. Shields, MD, said during his session announcing the new NCCN Guidelines.

Linda House Highlights the Effect of Strong Patient-Physician Relationships

March 14th 2015

Linda House Highlights the Effect of Strong Patient-Physician Relationships

Patient-provider dialogue before making treatment decisions affects how satisfied patients are with their overall care, Linda House, RN, BSN, MSM, president of the Cancer Support Community, said at the National Comprehensive Cancer Network 20th Annual Conference.

NCCN Guidelines Become Resource Stratified for Global Use

March 13th 2015

NCCN Guidelines Become Resource Stratified for Global Use

Laura Joszt, MA

Resource constraints may confine the ability of physicians to deliver optimal cancer care to all patients across the world, which the National Comprehensive Cancer Network is acknowledging by resource stratifying its Guidelines.

Dr Peter Bach Explains Diminishing Returns in Cancer Drugs

March 13th 2015

Dr Peter Bach Explains Diminishing Returns in Cancer Drugs

While the cost of introductory cancer drugs is increasing rapidly, there has not been a commensurate increase in benefit, according to Peter Bach, MD, with Memorial Sloan Kettering Cancer Center.

March 13th 2015

NCCN Recommends Only One Test for Breast Cancer, Says Expert

According to Dr Amy Cyr from the Siteman Cancer Center at Washington University in St. Louis, Missouri, while Oncotype DX is both prognostic and predictive, none of the other tests currently available have shown both capabilities.

March 13th 2015

Low Breast Density Could Indicate Poor Prognosis, Study Suggests

The findings of this study, conducted in Finland, may prove significant for the assessment of breast cancer prognosis and treatment planning.

March 13th 2015

CDC Report Underscores Impact of Early Diagnosis and Innovation on Cancer Survival

Two out of three people with metastatic disease survive 5 years or more, the report shows. The authors hope the data can help researchers develop better cancer control programs.

20 Years of Creating and Embracing Guidelines in Cancer Care

March 13th 2015

20 Years of Creating and Embracing Guidelines in Cancer Care

Laura Joszt, MA

When the first National Comprehensive Cancer Network Guidelines were developed 20 years ago, even the participating members who were there at the beginning were skeptical they would be able to come to an agreement and build something lasting.

March 13th 2015

Geography Determines Appropriate Use of Imaging in Low-Risk Cancer Patients

The study, published in JAMA Oncology, found that low risk breast and prostate cancer patients received unnecessary imaging overall, with a higher rate observed in the North East region of the country.

March 12th 2015

ACS Study Recommends Increased Screening to Reduce Incidence of Colorectal Cancer

The study, published in the journal Cancer found that increasing screening rates to 80% by 2018 would reduce projected colorectal cancer incidence rates by 17% and mortality rates by 19% during short-term follow-up, and by 22% and 33%, respectively, during extended follow-up. Those reductions would amount to a total of 277,000 averted new cancers and 203,000 averted colorectal cancer deaths from 2013 through 2030.

...

137 138 139 140 141 142 143 144 145

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions